<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02624440</url>
  </required_header>
  <id_info>
    <org_study_id>DMSG#01/12</org_study_id>
    <secondary_id>2012-004424-38</secondary_id>
    <nct_id>NCT02624440</nct_id>
  </id_info>
  <brief_title>Clarithromycin, Sulfamethoxazole/Trimethoprim or Observation in Newly Diagnosed Multiple Myeloma</brief_title>
  <acronym>SUTRICA</acronym>
  <official_title>A Randomized, Open-label Phase III Study of Clarithromycin, Sulfamethoxazole/Trimethoprim or Observation in Combination With Standard Therapy in Patients With Newly Diagnosed Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henrik Gregersen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Myeloma Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aalborg Universitetshospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of prophylactic antibiotics in multiple myeloma. One third of
      patients will received treatment with clarithromycin, one third of patients will receive
      treatment with sulfamethoxazole/trimethoprim and one third will be observed without
      prophylactic antibiotics. All patients receive concurrent anti-myeloma treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is a need for improvement of the prognosis in elderly myeloma patients. The patients
      are fragile due to age and severe comorbidity. Infections are frequent during the course of
      initial myeloma treatment and contribute to the high morbidity and mortality in elderly
      patients. Furthermore infections often lead to delay in myeloma treatment and to dose
      reduction. The use of primary antibiotic prophylaxis might influence the frequency of these
      complications. In the study myeloma patients who are ineligible for high-dose melphalan with
      stem cell support are randomised to either p.o. clarithromycin 250 mg twice daily for 180
      days, p.o. sulfamethoxazole/trimethoprim 400/80 mg twice daily for 180 days or observation
      without prophylactic antibiotics. All patients receive concurrent myeloma treatment at the
      discretion of the treating physician. The choice of anti-myeloma treatment has to be settled
      before randomization. The study evaluates the frequency of infections in patients treated
      with clarithromycin, sulfamethoxazole/trimethoprim or observation
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of frequency of infections in patients treated with clarithromycin, sulfamethoxazole/trimethoprim or observed without prophylactic antibiotic</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rates in the group of patients treated with clarithromycin compared to the other patients in the study</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of adverse events assessed by CTCAE v4.0 in patients treated with clarithromycin, sulfamethoxazole/trimethoprim or observed without prophylactic antibiotic</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of overall survival between patients treated with clarithromycin, sulfamethoxazole/trimethoprim or observed without prophylactic antibiotic</measure>
    <time_frame>Three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed by EORTC QLQ-MY20</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed by EORTC QLQ-C30</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>Clarithromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>p.o. clarithromycin 250 mg twice daily for 180 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sulfamethoxazole/trimethoprim</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>p.o. sulfamethoxazole/trimethoprim 400/80 mg twice daily for 180 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Observation without prophylactic antibiotic treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard myeloma treatment</intervention_name>
    <description>The choice of myeloma standard treatment is at the discretion of the treating investigator guided by the national Danish guidelines for treatment of multiple myeloma</description>
    <arm_group_label>Clarithromycin</arm_group_label>
    <arm_group_label>Sulfamethoxazole/trimethoprim</arm_group_label>
    <arm_group_label>Observation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>P.o. clarithromycin 250 mg twice daily</description>
    <arm_group_label>Clarithromycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfamethoxazole/trimethoprim</intervention_name>
    <description>P.o. sulfamethoxazole/trimethoprim 400/80 mg twice daily</description>
    <arm_group_label>Sulfamethoxazole/trimethoprim</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Observation</intervention_name>
    <description>Observation without prophylactic antibiotic</description>
    <arm_group_label>Observation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Myeloma diagnosis according to IMWG criteria

          -  Treatment demanding disease

          -  Signed informed consent given prior to any study related activities, except bone
             marrow samples for diagnosis, FISH, biobanking, and skeletal x-ray

          -  Age &gt; 18 years

        Exclusion Criteria:

          -  Allogeneic transplantation scheduled as a part of the treatment

          -  High-dose melphalan with stem cell support scheduled as a part of the treatment

          -  Myeloma treatment prior to entry in the study, except radiotherapy,
             bisphosphonates/denusumab or corticosteroids for symptom control

          -  Concurrent disease making clarithromycin or sulfamethoxazole/trimethoprim treatment
             unsuitable

          -  Positive pregnancy test (only applicable for women with childbearing potential)

          -  Known or suspected hypersensitivity or intolerance to claritromycin, sulfamethoxazole
             or trimethoprim

          -  Prolonged QT corrected (QTc) interval ( &gt; 500 msec on screening ECG)

          -  Concurrent treatment with cabergoline, fluconazole, ketoconazole, pimozide,
             quetiapine, sirolimus, verapamil, tacrolimus, ergot alkaloid or methotrexate

          -  Uncontrolled or severe cardiovascular disease including myocardial infarction within 6
             months of enrolment, uncontrolled angina or known cardiac amyloidosis

          -  Severe renal dysfunction (estimated creatinine clearance &lt;10 mL/min)

          -  Serious medical or psychiatric illness which, in the judgment of the investigator,
             would make the patient inappropriate for entry into the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrik Gregersen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aalborg Universitetshospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sanne Kjaer</last_name>
    <phone>+45 97663884</phone>
    <email>smk@rn.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ulla Kjaer</last_name>
    <phone>+45 97663882</phone>
    <email>u.kjaer@rn.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Hematology, Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Henrik Gregersen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Hematology, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Niels Frost Andersen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Hematology, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Annette Juul Vangsted, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Hematology, Esbjerg Sygehus</name>
      <address>
        <city>Esbjerg</city>
        <zip>6700</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Per Trøllund Pedersen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Hematology, Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carsten Helleberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Hematology, Hospitalsenheden Vest</name>
      <address>
        <city>Holstebro</city>
        <zip>7500</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Robert Schou Pedersen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Hematology, Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Niels Abildgaard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Hematology, Roskilde Hospital</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ulf Christian Frølund, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2015</study_first_submitted>
  <study_first_submitted_qc>December 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2015</study_first_posted>
  <last_update_submitted>December 4, 2015</last_update_submitted>
  <last_update_submitted_qc>December 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aalborg Universitetshospital</investigator_affiliation>
    <investigator_full_name>Henrik Gregersen</investigator_full_name>
    <investigator_title>Consultant</investigator_title>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Infection</keyword>
  <keyword>Clarithromycin</keyword>
  <keyword>Trimethoprim-Sulfamethoxazole Combination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

